Cultures were harvested at different time points after the addition of the lysed tumor cells and phagocytosis was determined by flow cytometry by gating on PKH26+ events and expressed as the percentage of CFSE+ events within the PKH26 gate.Isolation of PBMC and DC CulturePBMC were isolated by centrifugation on Ficoll-Hypaque (GE Healthcare, Uppsala, Sweden) from heparinized venous blood drawn from HD or HNSCC patients. moDC were generated as described previously [15]. Briefly, after isolation, 5?06106 PBMC were seeded onto 6-well-plates (Beckton Dickinson, Franklin Lakes, NJ) in AIM V Bexagliflozin medium (Gibco-Invitrogen, Carlsbad, CA) and incubated for 2 h. A small portion of PBMCs was used for HLA-A2-typing by flow cytometry. Non-adherent cells were removed and cryoperserved. Adherent cells were resuspended in RPMI1640 medium (Lonza) containing 1000 IU/ml GM-CSF (Bayer, Seattle, WA), 1000 IU/ml IL-4 (Cellgenix, Freiburg, Germany) and 10 (v/v) FBS (GibcoInvitrogen) and were cultured for 5 days. On day 5, immature DCIRX-2 Up-Regulates DC MaturationFlow Cytometry Based Cytotoxicity AssayCTL cytotoxicity was assessed by a modified flow cytometry based assay [41]. Briefly, PCI-13 and MCF-7 cells were stained with 2 mMol CFSE for 10 min at 37uC in the dark. Cells were washed and co-incubated with CTLs at various effector to target ratios for 4 h at 37uC. An aliquot of 1 mg/ml 7-aminoactinomycin D (7-AAD, Invitrogen) was then added to 
each tube, and the cells were incubated for an additional 20 min. Cells were acquired for analysis on a Beckman Coulter XL cytometer, detecting CFSE on FL1 and 7-AAD on FL4. Target cells were identified as CFSE-positive, and the percentage of 7-AAD positive target cells was determined. Target cells maintained for 4 h without CTL served as a negative control, and target cells incubated for 10 min at 56uC before a 4 h incubation served as a positive control for 7-AAD staining. The percentage of cytotoxic activity was calculated using the following formula: specific lysis = 7-AAD+ targets minus spontaneous 7-AAD+ targets. MCF7, a breast cancer cell line, was used as a specificity control in cytotoxicity assays. The HLA-class-I MedChemExpress Peptide M restriction of the cytotoxicity was tested by the preincubation of 1081537 the target cells with 10 mg/ml of mAb W6/32 [37].assisted image analysis (Zeiss ELISPOT 4.13.3, Jena, Germany). Background values (spots from wells containing mDC alone) were subtracted from experimental values (spots in wells containing mDC and CTL).Statistical AnalysisData were analyzed using unpaired and paired students t tests. The p values ,0.05 were considered significant.Supporting InformationFigure S1 APM expression in iDCs from HD and HNSCC 1527786 patients. (A) Immature monocyte derived DCs generated from PBMC of HD (white bars) express significantly higher levels of TAP1 and TAP2 (*, p,0.01) than those generated from PBMC of HNSCC patients (black bars). Tapasin, Calreticullin and LMP2 expression was not significantly different in HNSCC patients and HD. The DC APM expression was determined by flow cytometry. The data are mean percentages 6 SEM of cells positive for the indicated marker on cells obtained from 12 different HD and 12 HNSCC. (B) Representative histograms showing APM expression in iDC from HD and HNSCC patients. The shaded peaks represent isotype controls. (JPG) Table S1 
Phenotype of iDC from healthy donors (HD) and HNSCC patients*. (DOC) Table S2 Concentrations of cytokines in the IRX-2 lot 051308 used for the described.Cultures were harvested at different time points after the addition of the lysed tumor cells and phagocytosis was determined by flow cytometry by gating on PKH26+ events and expressed as the percentage of CFSE+ events within the PKH26 gate.Isolation of PBMC and DC CulturePBMC were isolated by centrifugation on Ficoll-Hypaque (GE Healthcare, Uppsala, Sweden) from heparinized venous blood drawn from HD or HNSCC patients. moDC were generated as described previously [15]. Briefly, after isolation, 5?06106 PBMC were seeded onto 6-well-plates (Beckton Dickinson, Franklin Lakes, NJ) in AIM V medium (Gibco-Invitrogen, Carlsbad, CA) and incubated for 2 h. A small portion of PBMCs was used for HLA-A2-typing by flow cytometry. Non-adherent cells were removed and cryoperserved. Adherent cells were resuspended in RPMI1640 medium (Lonza) containing 1000 IU/ml GM-CSF (Bayer, Seattle, WA), 1000 IU/ml IL-4 (Cellgenix, Freiburg, Germany) and 10 (v/v) FBS (GibcoInvitrogen) and were cultured for 5 days. On day 5, immature DCIRX-2 Up-Regulates DC MaturationFlow Cytometry Based Cytotoxicity AssayCTL cytotoxicity was assessed by a modified flow cytometry based assay [41]. Briefly, PCI-13 and MCF-7 cells were stained with 2 mMol CFSE for 10 min at 37uC in the dark. Cells were washed and co-incubated with CTLs at various effector to target ratios for 4 h at 37uC. An aliquot of 1 mg/ml 7-aminoactinomycin D (7-AAD, Invitrogen) was then added to each tube, and the cells were incubated for an additional 20 min. Cells were acquired for analysis on a Beckman Coulter XL cytometer, detecting CFSE on FL1 and 7-AAD on FL4. Target cells were identified as CFSE-positive, and the percentage of 7-AAD positive target cells was determined. Target cells maintained for 4 h without CTL served as a negative control, and target cells incubated for 10 min at 56uC before a 4 h incubation served as a positive control for 7-AAD staining. The percentage of cytotoxic activity was calculated using the following formula: specific lysis = 7-AAD+ targets minus spontaneous 7-AAD+ targets. MCF7, a breast cancer cell line, was used as a specificity control in cytotoxicity assays. The HLA-class-I restriction of the cytotoxicity was tested by the preincubation of 1081537 the target cells with 10 mg/ml of mAb W6/32 [37].assisted image analysis (Zeiss ELISPOT 4.13.3, Jena, Germany). Background values (spots from wells containing mDC alone) were subtracted from experimental values (spots in wells containing mDC and CTL).Statistical AnalysisData were analyzed using unpaired and paired students t tests. The p values ,0.05 were considered significant.Supporting InformationFigure S1 APM expression in iDCs from HD and HNSCC 1527786 patients. (A) Immature monocyte derived DCs generated from PBMC of HD (white bars) express significantly higher levels of TAP1 and TAP2 (*, p,0.01) than those generated from PBMC of HNSCC patients (black bars). Tapasin, Calreticullin and LMP2 expression was not significantly different in HNSCC patients and HD. The DC APM expression was determined by flow cytometry. The data are mean percentages 6 SEM of cells positive for the indicated marker on cells obtained from 12 different HD and 12 HNSCC. (B) Representative histograms showing APM expression in iDC from HD and HNSCC patients. The shaded peaks represent isotype controls. (JPG) Table S1 Phenotype of iDC from healthy donors (HD) and HNSCC patients*. (DOC) Table S2 Concentrations of cytokines in the IRX-2 lot 051308 used for the described.